Item 2.02. Results of Operations and Financial Condition.
In connection with the press release described in Item 8.01 below, on January 7,
2021, Eiger BioPharmaceuticals, Inc. (the "Company") provided, on a preliminary
and unaudited basis, certain estimates regarding its cash, cash equivalents and
investments as of December 31, 2020 on a pro forma basis. The estimate is a
preliminary estimate based on currently available information and does not
present all necessary information for a complete understanding of the Company's
financial condition as of December 31, 2020 or the Company's results of
operations for the year ended December 31, 2020.
Item 8.01. Other Events.
On January 7, 2021, the Company issued a press release titled "Eiger Updates on
2020 Progress and 2021 Plans." A copy of the press release is attached hereto as
Exhibit 99.1 and incorporated herein by reference.
Forward-Looking Statements
Statements in this report that are not strictly historical in nature constitute
"forward-looking statements." Such statements include, but are not limited to
the pro forma cash, cash equivalents and investments as of December 31, 2020.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors. More information about the risks the Company faces is
included under the headings "Risk Factors" in the Company's most recently filed
documents with the U.S. Securities and Exchange Commission. The Company is
providing this information as of this date and does not undertake any obligation
to update any forward-looking statements contained in this report as a result of
new information, future events or otherwise.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press release, dated January 7, 2021, titled "Eiger Updates on 2020
Progress and 2021 Plans."
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses